Skip to main content

Clinical Trials to Treat Kidney (Renal Cell) Cancer

Trials 76-100 of 122

Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C...
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Immunotherapy (Pembrolizumab or Nivolumab) with Metformin or Rosiglitazone for the Treatment of Advanced Solid Tumors
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
Inulin Gel in Combination with Ipilimumab and Nivolumab for the Treatment of Metastatic or Locally Advanced Kidney Cell Cancer, ICON Trial
Status: Active
Location: University of Michigan Rogel Cancer Center, Ann Arbor, Michigan
Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC)
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Study of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
177Lu Girentuximab in Combination with Cabozantinib and Nivolumab for the Treatment of Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Yttrium-90 (Y90) Radioembolization for the Treatment of Early Stage Renal Cell Carcinoma, The RENEGADE Trial
Status: Active
Location: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California
CD70 CAR Engineered IL15-Transduced Cord Blood-Derived NK Cells and Lymphodepleting Chemotherapy for the Treatment of Advanced Renal Cell Carcinoma, Mesothelioma and Osteosarcoma
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Status: Active
Location: USC / Norris Comprehensive Cancer Center, Los Angeles, California
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
E7777 and Pembrolizumab for the Treatment of Patients with Recurrent or Metastatic Cancer
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
ALG.APV-527 First-in-human Study
Status: Active
Location: Icahn School of Medicine at Mount Sinai, New York, New York
Personalized Neoantigen Peptide-Based Vaccine in Combination with Pembrolizumab for the Treatment of Advanced Solid Tumors, The PNeoVCA Study
Status: Active
Location: Mayo Clinic in Florida, Jacksonville, Florida
CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney Cancer
Status: Active
Location: City of Hope Comprehensive Cancer Center, Duarte, California
Genetically Engineered Cells (TGFβR-2 KO CD70 CAR NK Cell Therapy) with Lymphodepleting Chemotherapy for the Treatment of Unresectable or Metastatic Refractory Clear Cell Renal Cell Carcinoma
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Nivolumab and Ipilimumab with and without Camu Camu for the Treatment of Patients with Metastatic Renal Cell Carcinoma
Status: Active
Location: City of Hope Comprehensive Cancer Center, Duarte, California
The Immune Effects of Fermented Wheat Germ Nutritional Supplementation in Patients with Solid Tumor Cancers Being Treated with Standard of Care Checkpoint Inhibitors
Status: Active
Location: 5 locations
First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors
Status: Active
Location: Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah
Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors
Status: Active
Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri
Tumor Treating Fields Therapy (NovoTTF™-200M and NovoTTF-200A Systems) for the Treatment of Refractory Spinal Metastasis
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Tumor Treating Fields Therapy in Combination with Chemotherapy for the Treatment of Advanced Solid Tumors Involving the Abdomen or Thorax
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
AB821 for the Treatment of Unresectable or Metastatic Melanoma or other Recurrent, Locally Advanced, or Metastatic Solid Tumors
Status: Active
Location: Yale University, New Haven, Connecticut
A Study of MGC026 in Participants With Advanced Solid Tumors
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas